BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Oct 02, 2006
 |  BioCentury  |  Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes

Company Bank Analyst Coverage Opinion Wk chg 9/29 cls
Acorda (ACOR) Banc of America Securities David Witzke Price target Buy 312% $9.15
Lazard Joel Sendek Price target Buy
Witzke raised his target to $12 from $5 after the company's Fampridine-SR met all three endpoints in a Phase III trial to improve walking ability in patients with multiple sclerosis (MS). He expects the sustained-release formulation of 4-aminopyridine (4-AP) to be launched in 2010 (see "Phase III According to Phase II," A20).
Sendek raised...

Read the full 537 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >